[go: up one dir, main page]

LT2013015A - Farmacinės kompozicijos - Google Patents

Farmacinės kompozicijos

Info

Publication number
LT2013015A
LT2013015A LT2013015A LT2013015A LT2013015A LT 2013015 A LT2013015 A LT 2013015A LT 2013015 A LT2013015 A LT 2013015A LT 2013015 A LT2013015 A LT 2013015A LT 2013015 A LT2013015 A LT 2013015A
Authority
LT
Lithuania
Prior art keywords
pharmaceutical compositions
present
antibody
activated
treatment
Prior art date
Application number
LT2013015A
Other languages
English (en)
Other versions
LT5987B (lt
Inventor
Iljiich Oleg Epshtein
Alexandrovna Svetlana Sergeeva
Fyodorovna Liudmila Dolgovyh
Anatolievna Irina Kheyfets
Leonidovna Julia DUGINA
Alexandrovna Julia Zabolotneva
Sergey Alexandrovich Tarasov
Original Assignee
Epshtein Iliich Oleg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2013015(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Epshtein Iliich Oleg filed Critical Epshtein Iliich Oleg
Publication of LT2013015A publication Critical patent/LT2013015A/lt
Publication of LT5987B publication Critical patent/LT5987B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Išradimas skirtas farmacinėms kompozicijoms, turinčioms aktyvuotos-potencijuotos formos antikūno prieš žmogaus kanabinoidinį receptorių, ir jų panaudojimui nutukimo ir susijusių metabolinių sutrikimų gydymui. Dar šis išradimas skirtas farmacinėms kompozicijoms, turinčioms aktyvuotos-potencijuotos formos antikūno prieš žmogaus kanabinoidinį receptorių ir aktyvuotos-potencijuotos formos antikūno prieš S-100 baltymą, skirtoms panaudoti gydymui nuo priklausomybės nuo psichoaktyvių medžiagų.
LT2013015A 2010-07-15 2013-02-14 Farmacinės kompozicijos LT5987B (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома

Publications (2)

Publication Number Publication Date
LT2013015A true LT2013015A (lt) 2013-11-25
LT5987B LT5987B (lt) 2014-01-27

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2013015A LT5987B (lt) 2010-07-15 2013-02-14 Farmacinės kompozicijos

Country Status (30)

Country Link
US (1) US8865163B2 (lt)
EP (1) EP2593477A2 (lt)
JP (1) JP2013535436A (lt)
KR (1) KR20140012009A (lt)
CN (1) CN103124742A (lt)
AR (1) AR082246A1 (lt)
AU (1) AU2011278040B2 (lt)
BR (1) BR112013000841A2 (lt)
CA (1) CA2805091A1 (lt)
CL (1) CL2013000098A1 (lt)
CZ (1) CZ2013104A3 (lt)
DE (1) DE112011102349T5 (lt)
DK (1) DK201370078A (lt)
EA (1) EA029400B1 (lt)
EE (1) EE05760B1 (lt)
ES (1) ES2542042R1 (lt)
FI (1) FI20135146L (lt)
FR (1) FR2962653A1 (lt)
GB (1) GB2496076B (lt)
IT (1) ITTO20110641A1 (lt)
LT (1) LT5987B (lt)
MX (1) MX361778B (lt)
MY (1) MY158183A (lt)
NO (1) NO20130219A1 (lt)
NZ (1) NZ606768A (lt)
PE (1) PE20131338A1 (lt)
PH (1) PH12013500109A1 (lt)
SE (1) SE1350179A1 (lt)
SG (1) SG187037A1 (lt)
WO (1) WO2012007847A2 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2593140A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JP2013538791A (ja) * 2010-07-15 2013-10-17 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び泌尿生殖器系障害を治療する方法
CA2804967A1 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
ITTO20110632A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
CN103200964A (zh) * 2010-07-21 2013-07-10 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对与呼吸系统疾病或病症相关的疾病或病症进行治疗的方法
NZ606964A (en) * 2010-07-21 2015-08-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
PE20131065A1 (es) * 2010-07-21 2013-09-23 Oleg Iliich Epshtein Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
PH12013500232A1 (en) * 2010-08-06 2019-09-02 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
IL248006B2 (en) * 2014-03-27 2024-05-01 Bird Rock Bio Inc Antibodies that bind to human cannabinoid receptor 1
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
WO2017058771A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) recetor
DK4021505T3 (da) * 2019-08-29 2024-02-12 Oleg Iliich Epshtein Medikament til behandling af infektionssygdomme

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
IL125743A (en) 1996-02-12 2003-09-17 Epshtein Oleg Iliich Medicinal preparation containing an active medical substance with homeopathic potentiation
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
US20050100513A1 (en) 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
EA200802440A1 (ru) * 2006-06-06 2009-06-30 Олег Ильич ЭПШТЕЙН Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
TW200825067A (en) 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
CA2804967A1 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593138A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
NZ606964A (en) 2010-07-21 2015-08-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ITTO20110632A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
US20120258146A1 (en) 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
EP2596021A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating alzheimer's disease
PE20131065A1 (es) 2010-07-21 2013-09-23 Oleg Iliich Epshtein Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

Also Published As

Publication number Publication date
CZ2013104A3 (cs) 2013-05-29
EE05760B1 (et) 2016-03-15
KR20140012009A (ko) 2014-01-29
WO2012007847A3 (en) 2012-04-12
GB2496076A (en) 2013-05-01
US20130017202A1 (en) 2013-01-17
ES2542042A2 (es) 2015-07-29
AU2011278040B2 (en) 2016-06-02
EA201300133A1 (ru) 2014-03-31
MX361778B (es) 2018-12-17
PE20131338A1 (es) 2013-11-18
CA2805091A1 (en) 2012-01-19
NO20130219A1 (no) 2013-03-22
GB2496076B (en) 2018-05-09
SG187037A1 (en) 2013-02-28
AR082246A1 (es) 2012-11-21
NZ606768A (en) 2015-08-28
PH12013500109A1 (en) 2015-07-03
DK201370078A (en) 2013-02-14
US8865163B2 (en) 2014-10-21
AU2011278040A1 (en) 2013-03-07
CL2013000098A1 (es) 2015-01-16
FI20135146L (fi) 2013-02-15
FR2962653A1 (fr) 2012-01-20
SE1350179A1 (sv) 2013-04-12
ITTO20110641A1 (it) 2012-01-16
WO2012007847A2 (en) 2012-01-19
LT5987B (lt) 2014-01-27
EE201300005A (et) 2013-08-15
ES2542042R1 (es) 2015-10-06
EP2593477A2 (en) 2013-05-22
JP2013535436A (ja) 2013-09-12
BR112013000841A2 (pt) 2016-06-07
CN103124742A (zh) 2013-05-29
DE112011102349T5 (de) 2013-04-18
MY158183A (en) 2016-09-15
MX2013000545A (es) 2013-10-28
GB201302653D0 (en) 2013-04-03
EA029400B1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
LT2013015A (lt) Farmacinės kompozicijos
PH12013500111A1 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TW201129382A (en) Antibody formulation and therapeutic regimens
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
EP3156064A4 (en) Application of yb-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease
EA201491769A1 (ru) Фармацевтическая композиция с фиксированной дозой, содержащая мометазон и азеластин
EP2725101A4 (en) PROTEIN WITH TRUNKED FORM OF A PROTEIN FROM THE EXTRACELLULAR DOMAIN OF FRIZZLED 2 AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BONE DISORDERS WITH THIS PROTEIN
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
UA56025U (ru) Способ определения запрещенных наркотиков и сильнодействующих лекарственных средств в биологическом материале человека

Legal Events

Date Code Title Description
BB1A Patent application published

Effective date: 20131125

FG9A Patent granted

Effective date: 20140127

MM9A Lapsed patents

Effective date: 20180715